These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 18269343)

  • 1. CD70 as a therapeutic target in human malignancies.
    Grewal IS
    Expert Opin Ther Targets; 2008 Mar; 12(3):341-51. PubMed ID: 18269343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical characterization of SGN-70, a humanized antibody directed against CD70.
    McEarchern JA; Smith LM; McDonagh CF; Klussman K; Gordon KA; Morris-Tilden CA; Duniho S; Ryan M; Boursalian TE; Carter PJ; Grewal IS; Law CL
    Clin Cancer Res; 2008 Dec; 14(23):7763-72. PubMed ID: 19047103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting CD70 for human therapeutic use.
    Boursalian TE; McEarchern JA; Law CL; Grewal IS
    Adv Exp Med Biol; 2009; 647():108-19. PubMed ID: 19760069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV
    Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune modulator CD70 as a potential cisplatin resistance predictive marker in ovarian cancer.
    Aggarwal S; He T; Fitzhugh W; Rosenthal K; Feild B; Heidbrink J; Mesmer D; Ruben SM; Moore PA
    Gynecol Oncol; 2009 Dec; 115(3):430-7. PubMed ID: 19800108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel antibody-based therapeutic agents targeting CD70: a potential approach for treating Waldenström's macroglobulinemia.
    Law CL; McEarchern JA; Grewal IS
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):90-3. PubMed ID: 19362984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker.
    Oflazoglu E; Stone IJ; Gordon K; Wood CG; Repasky EA; Grewal IS; Law CL; Gerber HP
    Clin Cancer Res; 2008 Oct; 14(19):6171-80. PubMed ID: 18809969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigational antibody-drug conjugates for hematological malignancies.
    Polson AG; Ho WY; Ramakrishnan V
    Expert Opin Investig Drugs; 2011 Jan; 20(1):75-85. PubMed ID: 21142808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates.
    Law CL; Gordon KA; Toki BE; Yamane AK; Hering MA; Cerveny CG; Petroziello JM; Ryan MC; Smith L; Simon R; Sauter G; Oflazoglu E; Doronina SO; Meyer DL; Francisco JA; Carter P; Senter PD; Copland JA; Wood CG; Wahl AF
    Cancer Res; 2006 Feb; 66(4):2328-37. PubMed ID: 16489038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human Cripto-1 as a target for a cancer vaccine: WO2008040759.
    Bianco C; Salomon DS
    Expert Opin Ther Pat; 2009 Feb; 19(2):141-4. PubMed ID: 19441915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD200: a putative therapeutic target in cancer.
    Moreaux J; Veyrune JL; Reme T; De Vos J; Klein B
    Biochem Biophys Res Commun; 2008 Feb; 366(1):117-22. PubMed ID: 18060862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of costimulatory ligand CD70 on steady-state dendritic cells breaks CD8+ T cell tolerance and permits effective immunity.
    Keller AM; Schildknecht A; Xiao Y; van den Broek M; Borst J
    Immunity; 2008 Dec; 29(6):934-46. PubMed ID: 19062317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-targeted drugs for the therapy of cancer.
    Pietersz GA; Krauer K
    J Drug Target; 1994; 2(3):183-215. PubMed ID: 7812691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer.
    Jacobs J; Zwaenepoel K; Rolfo C; Van den Bossche J; Deben C; Silence K; Hermans C; Smits E; Van Schil P; Lardon F; Deschoolmeester V; Pauwels P
    Oncotarget; 2015 May; 6(15):13462-75. PubMed ID: 25951351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent antibody drug conjugates for cancer therapy.
    Senter PD
    Curr Opin Chem Biol; 2009 Jun; 13(3):235-44. PubMed ID: 19414278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-linked cytotoxic agents in the treatment of cancer: current status and future prospects.
    Ghose T; Blair AH
    J Natl Cancer Inst; 1978 Sep; 61(3):657-76. PubMed ID: 80453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD74: a new candidate target for the immunotherapy of B-cell neoplasms.
    Stein R; Mattes MJ; Cardillo TM; Hansen HJ; Chang CH; Burton J; Govindan S; Goldenberg DM
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5556s-5563s. PubMed ID: 17875789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibodies in therapy of solid tumors.
    Heimann DM; Weiner LM
    Surg Oncol Clin N Am; 2007 Oct; 16(4):775-92, viii. PubMed ID: 18022544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The CD70-CD27 interaction during the stimulation with dendritic cells promotes naive CD4(+) T cells to develop into T cells producing a broad array of immunostimulatory cytokines in humans.
    Hashimoto-Okada M; Kitawaki T; Kadowaki N; Iwata S; Morimoto C; Hori T; Uchiyama T
    Int Immunol; 2009 Aug; 21(8):891-904. PubMed ID: 19556308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.